Covista (CVSA)
NYSE:CVSA
Want to see CVSA full AI Analyst Report?
Top Page
Covista
(NYSE:CVSA)
Select Model
Select Model
Rating:78Outperform
Price Target:
$135.00
▲(14.49% Upside)
Action:ReiteratedDate:04/10/26
The score is driven primarily by strong financial performance (profitability and cash generation with improving leverage) and supportive technical strength (price above major moving averages with positive MACD). Guidance and earnings-call sentiment add a positive boost via raised EPS outlook, while the overall score is tempered by slowing revenue growth, near-overbought momentum signals, and the lack of dividend yield data.
Positive Factors
Sustained enrollment momentum
Multi-quarter enrollment growth across the platform drives recurring tuition revenue and improves utilization of digital and clinical delivery investments. Sustained increases, especially large online scale at Walden, provide durable top-line support and operating leverage across academic cycles over the medium term.
Negative Factors
Chamberlain enrollment and profit pressure
Weakness in the core nursing franchise threatens near-term revenue and margin stability because Chamberlain is a major tuition driver. Recovery depends on fall-cycle recruitment and conversion; multi-cycle softness could materially reduce consolidated cash flow and require prolonged marketing or price investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained enrollment momentum
Multi-quarter enrollment growth across the platform drives recurring tuition revenue and improves utilization of digital and clinical delivery investments. Sustained increases, especially large online scale at Walden, provide durable top-line support and operating leverage across academic cycles over the medium term.
Read all positive factors
Covista (CVSA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.96B
Dividend YieldN/A
Average Volume (3M)330.98K
Price to Earnings (P/E)12.3
Beta (1Y)0.61
Revenue Growth11.92%
EPS Growth26.43%
CountryUS
Employees10,371
SectorConsumer Defensive
Sector Strength42
IndustryPersonal Products & Services
Share Statistics
EPS (TTM)2.43
Shares Outstanding34,508,522
10 Day Avg. Volume266,711
30 Day Avg. Volume330,976
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)3.29
Price to Sales (P/S)2.64
P/FCF Ratio16.41
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue2.45
Enterprise Value/Gross Profit4.27
Enterprise Value/Ebitda10.79
Forecast
1Y Price Target
$153.75Price Target Upside30.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)7.91
Revenue Forecast (FY)$1.92B
Covista Business Overview & Revenue Model
Company Description
Adtalem Global Education, Inc. engages in the provision of post-secondary education. It operates through the following segments: Chamberlain, Walden, and Medical and Veterinary. The Chamberlain segment offers degree and non-degree programs in the ...
How the Company Makes Money
Adtalem generates the majority of its revenue from student tuition and related educational fees charged by its universities and professional schools. Key revenue streams include (1) tuition from undergraduate and graduate degree programs (notably ...
Covista Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
74
Positive
Cash Flow
77
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2022 | Jun 2020 | Jun 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.89B | 1.79B | 1.58B | 1.45B | 906.90M | 1.05B |
| Gross Profit | 1.08B | 1.02B | 886.10M | 774.10M | 460.02M | 567.84M |
| EBITDA | 428.91M | 427.31M | 346.96M | 377.42M | 241.05M | 265.51M |
| Net Income | 253.25M | 232.68M | 136.78M | 96.93M | 76.91M | 202.23M |
Balance Sheet | ||||||
| Total Assets | 2.61B | 2.75B | 2.74B | 2.81B | 3.08B | 2.23B |
| Cash, Cash Equivalents and Short-Term Investments | 56.28M | 199.60M | 219.31M | 272.19M | 476.38M | 500.52M |
| Total Debt | 729.55M | 774.00M | 847.85M | 896.19M | 1.30B | 527.19M |
| Total Liabilities | 1.24B | 1.32B | 1.37B | 1.35B | 1.78B | 915.41M |
| Stockholders Equity | 1.38B | 1.43B | 1.37B | 1.46B | 1.30B | 1.31B |
Cash Flow | ||||||
| Free Cash Flow | 368.01M | 287.57M | 246.88M | 165.90M | 152.32M | 68.09M |
| Operating Cash Flow | 427.89M | 337.90M | 295.77M | 191.91M | 192.20M | 107.69M |
| Investing Cash Flow | -57.35M | -41.92M | -47.85M | 23.74M | -56.69M | 382.52M |
| Financing Cash Flow | -507.32M | -316.02M | -301.80M | -288.51M | 676.47M | -256.11M |
Covista Technical Analysis
Positive
117.91
Price Trends
106.16
Positive
105.19
Positive
116.49
Positive
Market Momentum
2.34
Positive
62.41
Neutral
61.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVSA, the sentiment is Positive. The current price of 117.91 is above the 20-day moving average (MA) of 114.48, above the 50-day MA of 106.16, and above the 200-day MA of 116.49, indicating a bullish trend. The MACD of 2.34 indicates Positive momentum. The RSI at 62.41 is Neutral, neither overbought nor oversold. The STOCH value of 61.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CVSA.
Covista Risk Analysis
Covista disclosed 45 risk factors in its most recent earnings report. Covista reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Covista Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | $2.15B | 11.89 | 16.30% | 1.88% | 24.20% | 9.66% | |
78 Outperform | $3.96B | 12.32 | 17.76% | ― | 11.92% | 26.43% | |
77 Outperform | $1.79B | 13.67 | 7.85% | 2.99% | 3.02% | 20.69% | |
73 Outperform | $4.59B | 21.44 | 28.22% | ― | 7.07% | -0.27% | |
67 Neutral | $4.42B | 17.67 | 26.41% | ― | 8.64% | -1.04% | |
64 Neutral | $5.00B | 16.28 | 6.53% | 0.65% | 2.52% | -59.66% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
* Consumer Defensive Sector Average
CVSA
Covista
115.22
7.98
7.44%
PRDO
Perdoceo Education
33.94
9.23
37.35%
LOPE
Grand Canyon Education
169.07
-9.90
-5.53%
STRA
Strategic Education
78.40
-0.55
-0.70%
GHC
Graham Holdings
1,122.51
209.47
22.94%
LAUR
Laureate Education
30.10
9.45
45.81%
Covista Corporate Events
Business Operations and StrategyExecutive/Board Changes
Covista Launches Investor Newsletter, Highlights Healthcare Talent Strategy
Positive
Apr 9, 2026
On April 9, 2026, Covista released its inaugural investor newsletter, highlighting its role in addressing the U.S. healthcare workforce shortage, especially in rural areas, and its evolution from an education provider into a broader talent platfor...
Business Operations and StrategyPrivate Placements and Financing
Covista Refinances Debt with New Seven-Year Term Loans
Positive
Mar 3, 2026
On March 2, 2026, Covista Inc. amended its existing credit agreement with a syndicate of lenders led by Morgan Stanley Senior Funding, Inc., incurring new term loans totaling $510 million that mature on March 2, 2033, and lowering its term loan in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.